Zealand Pharma A/S Ord(ZLDPF)

Description: Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

---

Keywords: Biotechnology Diabetes Organ Systems Insulin Metabolic Disease Endocrine System Peptide Hormones Copenhagen Analog Hormone Recombinant Proteins Boehringer Ingelheim Glucagon Insulin Glargine Type 2 Diabetes Hypoglycemia Pancreas Short Bowel Syndrome Congenital Hyperinsulinism Diabetes Treatment Lixisenatide Gastrointestinal And Metabolic Diseases Glp 2 Severe Hypoglycemia Treatment Of Short Bowel Syndrome

---

Home Page: www.zealandpharma.com

Sydmarken 11
Copenhagen, 2860
Denmark
Phone: 45 88 77 36 00

---

Officers

Exchange: PINK

Country: US

Currency: US Dollar ($)